GlassScriptPhysician profile
David William Lesko
NPI 1154858504
$1,548.56
in general payments reported to CMS, 2019-2025
14 companies · $602 in 2025
The $602 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $97.80 · 2023: $475 · 2024: $374 · 2025: $602.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,450.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $253.52 | 2022-2025 | |
| Glaxosmithkline, LLC. | $238.55 | 2022-2025 | Nucala |
| Aerin Medical INC. | $197.66 | 2023-2025 | |
| Integra Lifesciences Corporation | $188.51 | 2023-2024 | Instruments-Orthopedic, Integra Duo, Microfrance |
| Genzyme Corporation | $179.21 | 2022-2025 | |
| Stryker Corporation | $148.29 | 2023-2025 | Clarifix, Xpress Ent Dilation System, Scopis Ent |
| Regeneron Healthcare Solutions, INC. | $134.51 | 2023-2025 | Dupixent |
| Jazz Pharmaceuticals INC. | $61.15 | 2022-2024 | |
| Inspire Medical Systems, INC. | $41.29 | 2023 | Inspire |
| Smith+Nephew, INC. | $27.85 | 2025 | Tula, Sinu-Foam |
| Axsome Therapeutics, INC. | $25.94 | 2024 | Sunosi |
| Resmed Corp | $19.00 | 2025 | |
| Hikma Pharmaceuticals USA | $16.78 | 2024 | Ryaltris |
| Astrazeneca Pharmaceuticals LP | $16.30 | 2025 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Lesko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.